1. FRI0496 Comparing tofacitinib safety profile in patients with psoriatic arthritis in clinical studies with real-world data. (15th June 2017) Authors: Curtis, JR; Yun, H; FitzGerald, O; Winthrop, K; Azevedo, VF; Burmester, G; Rigby, WFC; Kanik, KS; Rojo, R; Menon, S; Wang, C; Biswas, P; Hendrikx, T; Palmetto, N Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 676 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP0202 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: opal beyond, a randomised, double-blind, placebo-controlled, phase 3 trial. (15th June 2017) Authors: Gladman, DD; Rigby, WFC; Azevedo, VF; Behrens, F; Blanco, R; Kaszuba, A; Kudlacz, E; Wang, C; Menon, S; Hendrikx, T; Kanik, KS Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 135 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SAT0439 Integrated safety summary of tofacitinib in psoriatic arthritis clinical studies. (15th June 2017) Authors: Burmester, G; FitzGerald, O; Winthrop, K; Williams, G; Azevedo, VF; Rigby, WFC; Kanik, K; Wang, C; Biswas, P; Jones, T; Menon, S; Palmetto, N; Rojo, R Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 938 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗